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Background: Increasingly, women with cystic ﬁbrosis become pregnant. Outcomes of these women need further study particularly in the setting of
improved survival in CF.
Methods: We performed a case-control study of pregnant CF women including 22 matched pairs with an average follow-up of 4.5 years.
Nutritional outcomes, changes in lung function, and exacerbation rates were compared.
Results:Matched pairs were similar in age, sweat chloride, FEV1 and FVC % predicted, BMI, and diabetes status. Change in BMI, FEV1 and FVC
% predicted at the end of pregnancy and at last follow-up were similar between groups. Moreover, rates of exacerbation before, during and after
pregnancy were similar. On multivariable analysis pregnancy had no effect on change in lung function over the study period. Signiﬁcant predictors
of decline included higher pre-pregnancy lung function and pancreatic insufﬁciency.
Conclusions: Pregnancy does not lead to immediate or medium-term adverse effects for CF patients.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Pregnancy; Nutrition1. Introduction
The life expectancy for people with cystic fibrosis (CF) has
been steadily rising due in part to improvements in manage-
ment and expanded treatment options. According to the 2011
Annual Data Report from Cystic Fibrosis Patient Registry, the
median predicted age of survival is approaching 40 years [1].
Coincident to improvements in survival, patients are leading
healthier and longer lives, and career and family planning is more
common for those with CF. As a result, an increasing number of
women are becoming pregnant, and recently the 2011 Cystic
Fibrosis Patient Registry reported that 211 women with cystic
fibrosis became pregnant this past year [1]. Unfortunately, little is⁎ Corresponding author at: Pulmonary, Allergy and Critical Care, University o
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,lishedknown regarding outcomes of cystic fibrosis patients who become
pregnant in the most recent era, when compared to peers with
similar nutritional and pulmonary status.
Preconception care, including optimizing pulmonary func-
tion, improved nutrition and controlling infections more aggres-
sively, favors pregnancy outcomes [2]. Recent studies have
confirmed this approach by documenting successful out-
comes obtained in pregnant women with CF, with appropri-
ate antepartum, intrapartum and postpartum care [3]. Overall,
pregnancy is tolerated well in CF patients with mild disease.
In contrast, women with poor pulmonary function, inadequate
nutrition, and pulmonary hypertension are at greater risk for
maternal and fetal morbidity and mortality. One study found that
preterm birth prevalence was as high as 40% in pregnancies of
patients with these comorbidities [2]. However, pregnancy in CF
patients can lead to little adverse effects in body weight in the
post-partum period [4]. Others have documented a decline in
post-pregnancy forced expiratory volume in one second (FEV1)
and body mass index (BMI) compared to pre-pregnancy values;by Elsevier B.V. All rights reserved.
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neonate birth weight were noted [5]. Pregnancy has also been
associated with increased antibiotic use and number of
hospitalizations [6]. FEV1 below 50% predicted, the presence of
Burkholderia cepacia, and pancreatic insufficiency have been
suggested as predictors of negative outcomes [7]. In summary,
these studies suggest that outcomes in pregnant patients with CF
need further study, preferably in larger populations and in a more
modern era, as new advancements in the field have improved
overall survival in CF patients.
We report a matched, case-control study of women with cystic
fibrosis who became pregnant and compare their outcomes to
women with similar nutritional status, age and lung function but
who have never been pregnant. By exploring the outcomes of
pregnancy in cystic fibrosis patients, health care professionals can
use all the data available to them while educating patients on the
risks of pregnancy. The current study is small, but adds further
information to the current literature.
2. Methods
This study was approved by the Institutional ReviewBoards at
both Universities affiliated with two adult Cystic Fibrosis Centers
in a major metropolitan area (University of Pennsylvania and
Drexel University College of Medicine). No personal identifiers
were used during the process of data collection.
A two center case-controlled study was performed to examine
the outcomes of pregnant cystic fibrosis patients who carried
fetuses beyond second trimester (Group A) compared to non-
pregnant CF patients (Group B) between 2001 and 2008. Women
between 18 and 38 years of age were included.
2.1. Data collection
Demographic and clinical data was extracted from the
electronic medical records. Other variables collected included
genotype and sweat chloride. Nutritional status (BMI), lung
function (FEV1% predicted), CF-related diabetes, and the number
of pulmonary exacerbations were documented during four specific
time periods: before pregnancy, end of pregnancy, after pregnancy
and at last follow-up (Figs. 2 and 3). Before pregnancywas defined
as a time period between 1 week and 3 months prior to conception
or an estimated time of 10–12 months prior to the delivery date.
End of pregnancywas defined as early as 2 days up to 3 months of
time after delivery. After pregnancy was between 3 months up
to 12 months after delivery. Last follow-up period included
results from 12 months up to 5 years after delivery. The average
follow-up time was 4.5 years. A timeline graph shown in Fig. 1Fig. 1. Timeline graph depicting time period when data was collected in each
group (before pregnancy, end of pregnancy, after pregnancy and at last follow-up).defines the time periods indicated by the various groups
aforementioned.
In addition, information on microbiology, liver function,
vitamin levels and osteoporosis was obtained. Hospitalizations,
transplantation or death were documented. Finally, information
on education, insurance and marital status was also obtained.
Fetal outcomes were tracked, including stillbirths, prematurity,
developmental issues and other problems. However, pregnan-
cies that were terminated prior reaching the latter of the 2nd
trimester were not documented.
Group A patients were then matched to other female patients
who have not become pregnant (Group B) and are followed by
the Adult Cystic Fibrosis clinics; first based on age, then based
on lung function and finally based on nutritional status. Data
described as above was also obtained for the control patients.
2.2. Statistical analysis
Analyses were made by student t-test or its non-parametric
equivalent to compare the two groups of CF patients. Multivar-
iable linear regression was used to estimate predictors of loss of
lung function in the sample of patients. Pregnant patients who
could not be individually matched to a non-pregnant patient
based on age, FEV1 and BMI were not included in this study.
Also, patients whose information was not available at the end of
pregnancy and after pregnancy due loss to follow-up were not
included.
3. Results
In the combined Adult Cystic Fibrosis Centers, there are a
total of 295 patients in the registry at the end of the study. The
median FEV1% predicted was 65.14 and the median BMI was
22.0 kg/m2 for the combined cohort from both centers based on
the Annual Data Report at the end of the study. A total of 31.5%
of female patients in the programs had carried out pregnancies
resulting in birth; however, not all pregnancies were included in
this case-controlled study as mentioned above. In addition, there
was one early termination of pregnancy (first trimester) because
of patient preference (patient moderate lung dysfunction, but feltFig. 2. Average Body Mass Index (BMI) during various time periods in pregnant
and non-pregnant cystic fibrosis patients. The follow-up period represents an
average of 4.5 years after pregnancy. There is no significant difference in change
between BMI at baseline and BMI at the end and after pregnancy (p N 0.2).
Fig. 3. Average FEV1% predicted during various time periods in pregnant and
non-pregnant cystic fibrosis patients. There is no significant difference between
FEV1% at baseline and at the end and after pregnancy when comparing pregnant
and non-pregnant CF patients (p N 0.2).
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pregnancies terminated during the study period.
A total of 44 subjects were studied, 22 representing the
pregnant group, and 22 representing the non-pregnant group.
Table 1 specifies the characteristics of pregnant patients and
non-pregnant patients. In the 22 matched pairs of patients
(pregnant vs. non-pregnant) studied, there were no noted
differences in age (p N 0.2), sweat chloride (p = 0.138), FEV1%
predicted (p N 0.2), FVC% predicted (p N 0.2), BMI (p N 0.2) or
diabetes (p N 0.2). There was a trend towards decreased rates of
pancreatic insufficiency in the pregnant group; however, this did
not reach statistical significance (p = 0.057). Additional infor-
mation is provided in Table 1.
Changes in lung function and nutritional status among the
pregnant and non-pregnant CF patients are reported below in
Table 2. Differences in lung function and BMI were determined
according to changes before pregnancy, at the end of pregnancy,Table 1
Characteristics outlined in both pregnant and non-pregnant female patients with cys
Group A (preg
Number of subjects 22
Age (years) 30.5 ± 6.4
Sweat chloride (mM) 95.8 ± 27.1
FEV1% predicted (baseline) 68.2 ± 18.5%
FVC% predicted (baseline) 87.5 ± 17.6%
Baseline body mass index, (BMI, kg/m2) 21.5 ± 3.6
Diabetes at baseline, n (%) 7 (31.8%)
Pseudomonas aeruginosa (%) 62.5%
Pancreatic insufficiency, n (%) 15 (68.2%)
Exacerbations per patient 1-year pre-pregnancy, n 0.38 ± 1.16
Genotype
DF508 homozygous 5 (22.7%)
DF508 heterozygous 11 (50%)
Other 6 (27.3%)
Marital status (P = 0.001)
Married n (%) 12 (54.5%)
Single n (%) 8 (36.4%)
Other n (%) 2 (9.1%)
Education
College n (%) 16 (72.8%)
High school n (%) 5 (22.7%)
Other n (%) 1 (4.5%)and after pregnancy. Number of exacerbations during pregnancy
and after pregnancy is also noted in both groups. There were no
differences in the rate of exacerbations before, during and after
pregnancy between the two groups (p N 0.2). There were no
differences in the change of BMI between the two groups at the end
of pregnancy (p N 0.2). The rest of the information is provided in
Table 2. In addition there were no differences in BMI and lung
function at last follow-up.
On multivariable regression analysis pregnancy had no effect
on change in lung function from pre-pregnancy to last follow-up.
The only significant predictors of decline were higher lung
function at the beginning of the study (p b 0.001) and pancreatic
insufficiency (p = 0.036). In a similar analysis of predictors of
BMI change, only lower BMI at the beginning of the study was a
predictor of further drop after pregnancy (p = 0.037). Unfortu-
nately, pregnancy is not free of complications and cystic fibrosis
increases risk for maternal and fetal complications. Among the 22
pregnant CF patients, a total of 2 patients encountered complica-
tions during the delivery of the neonate. One individual with a
baseline FEV1% predicted of 45.5% and BMI 18.9 kg/m
2 had
undergone a cesarean delivery complicated by the development of
respiratory failure with FEV1% predicted of 25%, and subse-
quently underwent lung transplantation after her pregnancy with
success. This patient was matched to a never pregnant patient who
received a lung transplant within the same period of time. Another
individual suffered complications during delivery and the neonate
had to be transferred to the NICU. One more baby had congenital
diaphragmatic hernia. No babies were delivered before 36 weeks.
The mothers did not have lower lung function or poor nutrition.
Two patients in the never pregnant group received lung transplants
during the time periods defined as after pregnancy and follow-up.
Matched pregnant patients did not receive a lung transplant.tic fibrosis. 22 pregnant patients were matched to 22 non-pregnant patients.
nancy) Group B (not pregnant) p-value
22
30.5 ± 5.0 p N 0.2
107.2 ± 15.5 p = 0.138
68.2 ± 18.7% p N 0.2
87.0 ± 16.2% p N 0.2
20.5 ± 1.7 p N 0.2
11 (50%) p N 0.2
81.3% p N 0.2
20 (90.9%) p = 0.057
0.24 ± 0.54 p N 0.2
p N 0.2
5 (22.7%)
11 (50%)
6 (27.3%)
p = 0.065
5 (22.7%)
10 (45.4%)
7 (31.9%)
p N 0.2
11 (50%)
7 (31.9%)
4 (18.1%)
Table 2
Change in FEV1% predicted, FVC% predicted and BMI before pregnancy and end of pregnancy seen in pregnant patients compared to those seen in non-pregnant
patients.
Group A
Pregnancy
Group B
No pregnancy
p-Value
FEV1% predicted change at end of pregnancy −3.2 ± 11.5% −4.7 ± 10.5% p N 0.2
FVC% predicted change at end of pregnancy −0.9 ± 16.6% −6.6 ± 18.0% p N 0.2
Body mass index (BMI) change at end of pregnancy 0.27 ± 1.45 −0.04 ± 1.13 p N 0.2
Exacerbations during pregnancy per patient 0.19 ± 0.60 0.14 ± 0.36 p N 0.2
FEV1% change 1-year post-pregnancy −5.4 ± 20.1% 1.1 ± 25.9% p N 0.2
FVC% change 1-year post-pregnancy −5.0 ± 18.0% −1.7 ± 21.6% p N 0.2
Body mass index (BMI) change 1-year post-pregnancy −0.38 ± 1.29 −0.09 ± 1.14 p N 0.2
Exacerbations after pregnancy per year per patient 0.48 ± 0.88 1.06 ± 1.94 p N 0.2
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As the median survival of patients with cystic fibrosis
continues to increase, women aremore likely to conceive and carry
pregnancies to term. Pregnancy, however, results in increased
physical demands and can have the potential to worsen the chronic
disease state. Theoretically, pregnancy can pose increased risk in
cystic fibrosis patients as decreased lung function can worsen with
increased abdominal girth and increased minute ventilation and
oxygen demand. Moreover, right heart failure can further ensue
during pregnancy. Along with physiologic changes of pregnancy,
several antibiotics routinely used to treat pulmonary exacerba-
tions may carry increased risks and side effects to the fetus.
Additionally, chest physiotherapy often becomes more difficult
to perform with increased gestation. Weight gain is an essential
component for fetal growth and development, and cystic fibrosis
patients often encounter problems gaining weight during pregnan-
cy. Pregnancy in cystic fibrosis patients also poses a greater risk for
the gestational diabetes and associated complications [6]. In
general, pre-pregnancy FEV1 and BMI have been shown to be
important predictors of outcome measures in cystic fibrosis
patients [8,9].
Despite the myriad risks theorized to pregnant women with
CF, the desire to have children often outweighs the risks. With
new advances in management and treatment, patients are able
to have successful outcomes after pregnancy. A multidisciplinary
approach to management of patients during pregnancy has been
well established recently [3,5–7,10–14]. Proper counseling,
frequent follow-up with a nutritionist and high-risk obstetrics/
gynecology specialists, and appropriate treatment of infections
during pregnancy have all been documented to promote healthy
outcomes in pregnancies [3,5–7,10–14].
In 2006, a case control multicenter study of 216 pregnant
women reported that there were no worse outcomes in pregnant
CF patients as they had similar respiratory trends in a decline in
FEV1 and similar health trends in increased prevalence of diabetes
as non-pregnant women [10]. Of note, baseline FEV1 values were
slightly higher in pregnant patients at 74.5% predicted compared to
non-pregnant patients at 66.4% [10], possibly suggesting that
women who become pregnant tended to be healthier. Due to
increased close monitoring and frequent visits during pregnancy,
patients had also received more therapy [10].Our study demonstrates that women with CF who become
pregnant do not have worse outcomes compared to non-pregnant
women. In pregnant patients, in comparison to non-pregnant
patients, there was a minimal weight loss of 1.5 kg within one
year after delivery. Nutritional status is impacted by pancreatic
insufficiency, malabsorption and energy expenditure in CF
patients. A decline in BMI is likely attributable to increased
energy expenditure as the patient is caring for her baby and
possibly breast-feeding. After one year postpartum, the patient is
able to gain weight back to her appropriate baseline. Overall,
pregnancy did not result in a decrement in nutritional status in
cystic fibrosis patients. Relative stability in pulmonary function
tests, nutritional status and number of exacerbations requiring
hospitalizations was noted, and there was no difference between
rates of change between pregnant and non-pregnant women. Our
findings are consistent with other recent studies [7,10,15,16]
evaluating the outcomes of pregnancy in CF patients.
In contrast to previous studies, this study was based on a
thorough evaluation in lung function and nutritional status in the
antepartum and post-partum periods. We assessed medium-term
impacts of pregnancy on cystic fibrosis patients in a more modern
era. Both patient groups were appropriately matched and baseline
FEV1 percentage values were similar; thus, the absence of
worsened outcomes cannot be attributed to better nutritional and
pulmonary health prior to conception. Among a total of 4 patients
who received a lung transplant, two patients in the non-pregnant
group were matched to pregnant patients who never received a
lung transplant.
This study has several limitations. The sample size is small and
as a result, even modest differences between the groups may have
been missed. In addition, we only have follow-up in patients of
4.5 years. This is not enough time to explore long-term results of
pregnancy and motherhood for women with CF. Finally, inherent
differences in patients who became pregnant and ones that did not
might still exist and matching is not able to completely account for
these differences. Larger studies are needed to determine whether
any subgroups of patients have increased morbidity with
pregnancy.
In conclusion, our study adds to the current literature
suggesting that pregnancy in carefully selected patients with
cystic fibrosis is feasible and successful even after medium-
term follow-up and after comparison to patients with similar
73M. Ahluwalia et al. / Journal of Cystic Fibrosis 13 (2014) 69–73disease severity. However, evidence on long-term outcomes is
still lacking.
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